

# In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate

Targeted thorium conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for the targeted alpha therapy (TAT) of cancer. Cell surface glycoprotein mesothelin is highly expressed in many human cancers. Mesothelin targeted thorium-227 conjugate (MSLN-TTC, BAY 2287411), comprising a mesothelin targeted antibody (MSLN-Ab), covalently attached to 3,2-HOPO chelator, enabling specific complexation and delivery of the alpha particle emitter thorium-227 ( $^{227}\text{Th}$ ) to tumor cells, is currently in a phase 1 clinical trial (NCT03507452). 3,2-HOPO systems are also very efficient chelators for zirconium-89 and it has therefore been suggested that positron emission tomography (PET) imaging provides a useful surrogate for understanding  $^{227}\text{Th}$  radio-immunotherapy. Hence, we describe the radiolabeling of the conjugated MSLN-Ab conjugate with the PET isotope zirconium-89 ( $^{89}\text{Zr}$ ) and show data from a biodistribution study comparing both thorium and zirconium conjugates.

### Email Address

olav.ryan@bayer.com

### Presentation Type

Poster

**Primary author:** Dr RYAN, Olav Benjamin (Bayer AS)

**Co-authors:** Dr CUTHBERTSON, Alan (Bayer AS); Dr KRISTIAN, Alexander (Bayer AS); Dr INDREVOLL, Baard (Bayer AS); Dr KARLSSON, Jenny (Bayer AS); Dr BJERKE, Roger M (Bayer AS); Dr HAGEMANN, Urs B (Bayer AG)

**Presenter:** Dr RYAN, Olav Benjamin (Bayer AS)